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Abstract: Maraviroc is the first and, so far, the only licensed representative of the class of   
chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunode-
ficiency virus (HIV) infection. Its safety and efficacy were demonstrated in several clinical 
trials, and its use was approved in 2007 by the responsible authorities. Some specific issues are 
correlated with maraviroc and its use. It is the only drug in the antiretroviral armamentarium, 
which does not interact with the viral enzymes but with a human receptor. Hence, it is able to 
be long-term effective only if the infecting virus uses, exclusively, the CCR5 receptor. Occur-
rence and detection of the CCR5 tropism are some of the great challenges of maraviroc use 
in treatment-experienced patients. Although up to 80% of naive patients harbor CCR5-tropic 
virus, the occurrence of CXCR4 or other tropisms increases with the duration of HIV infection 
and treatment. Nonetheless, maraviroc is a potent medication for eligible patients and helps to 
improve the outcome of antiretroviral treatment (ART) of HIV infection.
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Introduction
Since the discovery of the human immunodeficiency virus-1 (HIV-1) in 1983 and the 
beginning of the battle against acquired immunodeficiency syndrome, the development 
of antiretroviral medication has succeeded substantially. The development and use of 
antiretroviral therapy (ARV) started in the mid to end of the 1980s with the first class 
of substances, the nucleoside reverse transcriptase inhibitors (NRTIs).1 In the following 
years, additional substances and classes have been introduced into clinical practice. 
Until now, 5 classes of ARV with more than 20 licensed drugs have been established 
for therapeutic use. The armamentarium predominantly includes substances influencing 
viral enzymes. Most of the proven substances inhibit the reverse transcriptase (RT) 
either as nucleoside antagonists or as non-NRTIs; others work as protease inhibitors 
(PIs) or integrase inhibitors by modifying the viral enzymatic activity. However, these 
substances are underlying a risk to select resistant viral mutants due to the variability of 
the virus under pharmacological pressure. The only antiretroviral class not interfering 
with the enzymes of the virus is the group of entry inhibitors.
Different substances, each with a specific mode of action, are represented within 
this class. The first one is enfuvirtide, which has been licensed in 2003. The potency of 
this fusion inhibitor is based on its ability to block the conformational change of gp41 
and to avert the approach of virus and cell membrane.2 Despite the proven efficacy, 
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as subcutaneous injections twice daily and the resultant side 
effects predominantly present as cutaneous irritations and 
painful indurations.
Maraviroc
Lacking the disadvantages of enfuvirtide, maraviroc was the 
first, and is still the only, approved entry inhibitor in oral 
formulation that showed potency and sustained efficacy to 
suppress HIV-1 viral load.
Mechanism of action
The mechanism of action of maraviroc is based on the need of 
HIV-1 to use a main receptor (CD4) and a coreceptor (CCR5 
or CXCR4) on the surface of the target cells. HIV-1 attaches 
with its glycoprotein 120 (gp120) to the CD4 receptor. This 
is followed by a conformational change of gp120 and the 
coreceptor binding, which allows for the next step, the fusion 
of virus and cell membrane mediated by gp41.3,4
In 1996, Huang et al5 demonstrated that a homozygous, 
32-base pair mutation in the gene for CCR5 (∆32) protects 
against HIV infection by coding for a dysfunctional protein, 
which is not expressed on the cell surface. The later genetic 
studies demonstrated relatively high rates of 15%–20% of 
heterozygous ∆32 mutations in Caucasian populations, but 
rare cases in other populations. In 1996, Liu et al6 estimated 
that approximately 1% of the Caucasian population appeared 
to be homozygous for this ∆32 mutation. In fact, some of 
these individuals remained HIV-negative despite repeated 
exposure to HIV .
Based on this knowledge, it was found that maraviroc 
inhibits the attachment of HIV to its target cell via an allos-
teric modification of the CCR5 on the surface of the CD4+ 
cells. It works as a small molecular CCR5 inhibitor through 
a binding in a cavity in the transmembrane CCR5 receptor. 
This fixation of maraviroc changes the geometry of the 
transmembrane protein, which is originally needed for the 
binding of gp120 and CCR5.7–10
Coreceptor usage of HIV
Although HIV-1 predominantly uses the CCR5 coreceptor for 
cell infection, it is not the only possibility to operate. Some 
viral strains have the ability to use a second coreceptor called 
CXCR4 to infect the target cells, and some viruses may use 
both CCR5 and CXCR4 receptors.
Epidemiological studies revealed that HIV-1 strains in 
ARV-naive patients predominantly exhibit CCR5 tropism 
(R5 viral variants).11–13 More than 80% of treatment-naive 
HIV-1-infected individuals carry R5 viruses, whereas 
approximately 20% show dual-tropic or mixed-tropic viruses 
(R5/X4 variants). Only a minority (,1%) of viral strains 
are capable of using CXCR4 coreceptors exclusively (X4 
variants). In treatment-experienced populations, R5 variants 
still account for 48%–62% of isolates and R5/X4 variants are 
found in 34%–50% of these patients, whereas viruses that 
exclusively use the CXCR4 coreceptors for cell entry are seen 
in only 2%–4% of the pretreated population.14–16
The clinical relevance of CCR5 receptor variants, espe-
cially the homozygous one, is still unclear. Most recent 
studies suggest an association of ∆32 mutation and elevated 
mortality in cases of West Nile virus infections.17,18 In con-
trast, earlier studies suggested protection against chronic 
hepatitis B infection and rheumatoid arthritis or prolonged 
survival of renal transplant individuals.19–21 Additionally, an 
evaluation date back to the end of the last millennium dis-
cussed prevention of Yersinia infections (bubonic plague).22 
In fact, many issues have been discussed but a final conclu-
sion of the individual relevance of the CCR5 has not been 
established.
Tropism testing in daily clinical practice
As maraviroc cannot prevent cell infection in X4 or R5/X4 
variants, it is necessary to detect viral tropism carefully in 
each individual before using it for ARV . As there are differ-
ent methods to determine the tropism of the virus, it is still 
unclear which test is the most appropriate for routine clinical 
use. One can choose either phenotypic or genotypic methods, 
which differ substantially.
Phenotypic assays are based on the transfection of the 
virus into the cell culture, to mark the cell with a luciferase 
reporter gene, and on the determination of lyzed CCR5 or 
CXCR4 positive cell, in which a single viral cycle has been 
completed. Finally, the luciferase activity is measured by 
relative light units.23,24 Despite being considered to be the gold 
standard for the measurement of HIV-1 coreceptor usage, the 
phenotypic method has some disadvantages that should be 
kept in mind: the method is technically complex, expensive, 
and laborious. Only specialized laboratories with sophis-
ticated equipments are able to operate these complicated 
methods. In fact, performance of a phenotypic tropism test 
takes up to 4 weeks from blood drawing and costs between 
$750 and $1000.
In contrast, genotypic assays may be performed within 
some days, and the cost is restricted to the performance 
of a gene amplification, mostly of the V3 region. Sub-
sequently, the amplification products are analyzed in a 
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several standard sequences. For interpretation, some of the 
  algorithm systems predicting coreceptor usage are available 
online. These systems, such as Webcat, WebPSSM, and 
geno2pheno[coreceptor], are accessible via the Internet. 
Established laboratories use these systems to determine 
the coreceptor usage. A restriction of these systems is the 
relatively low sensitivity and specificity, but combining 2 or 
3 systems enhances the recall ratio.25–27
Clinical development of maraviroc
Because of the importance of coreceptors for viral entry and 
the knowledge of research in other entry inhibitors, the Pfizer 
Global Research and Development discovered maraviroc 
(UK-427,857) as a highly promising substance to block the 
CCR5 receptor effectively.
Clinical studies started with dose-finding and safety issues 
as short-term monotherapy administration in treatment-naive 
patients and in antiretroviral treatment (ART)-experienced 
patients, who had to be on treatment for at least 8 weeks 
(A4001007 and A4001015). Participation was restricted 
to individuals with confirmed R5 viral variants, viral 
load .5,000 HIV-1 copies/mL, and moderate immunodefi-
ciency with still more than 250 CD4+ cells/mm3. Results of 
these trials demonstrated efficacy of maraviroc in both naive 
and experienced patients with R5 but not with X4 viruses.28
Following trials (MOTIVATE-1 and MOTIVATE-2) 
evaluated the efficacy of maraviroc in treatment-experienced 
patients harboring R5-tropic variants. Both trials were 
double-blind, placebo-controlled, multicenter phase 2b/3 
studies, investigating maraviroc plus optimized background 
therapy (OBT) vs placebo plus OBT in viremic patients (viral 
load .5000 copies/mL) carrying CCR5-tropic virus. The 
treatment groups were also divided into patients receiving 
maraviroc once or twice daily. MOTIVATE-1 was conducted 
in the United States and Canada, whereas the identically 
designed MOTIVATE-2 trial enrolled patients in Europe, 
Australia, and North America. The primary end point of both 
studies was viral load change in HIV-1 RNA from baseline 
to week 48. According to the inclusion criteria, all patients 
had to be triple-class experienced. The results showed a sig-
nificant advantage for patients in the maraviroc groups: viral 
load declined by 1.66 log10 copies/mL and 1.82 log10 copies/
mL for once-daily and twice-daily administration of drug, 
respectively, whereas in the placebo arm, it declined only 
by 0.80 log10 copies/mL in MOTIVATE-1. Nearly the same 
results could be found in MOTIVATE-2: 1.72 and 1.87 log10 
reduction vs 0.76 log10 reduction, respectively. The study data 
also showed a superior response of CD4 cells in the   treatment 
arms: the mean increase of CD4 cells in MOTIVATE-1 
was 113 and 122 cells/µL for once-daily and twice-daily 
administration, respectively, vs 54 cells/µL in the placebo 
arm. In MOTIVATE-2, the CD4 cells increased by 122 and 
128 cells/µL for once-daily and twice-daily administration, 
respectively, (verum) and 69 cells/µL (placebo).
The pooled safety analysis of both studies demonstrated 
no statistical significant differences in treatment-related 
adverse events, which indicates a good compatibility of 
maraviroc.29–31
The results of the MOTIVATE studies led to the approval 
of maraviroc, with the restriction for use in pretreated patients 
harboring only R5-tropic viral strains.
A further study called MERIT compared maraviroc plus 
zidovudine/lamivudine with efavirenz plus the same back-
bone in ARV-naive patients. The original study missed its 
goal to demonstrate noninferiority of maraviroc correlated 
to efavirenz according to the rate of viral load ,50 copies/
µL after 48 weeks. However, it demonstrated the very good 
compatibility of the CCR5-inhibitor: patients following the 
efavirenz-containing regimen discontinued their therapy 
thrice, more often than maraviroc recipients did.
Later analyses verified that the original goal of nonin-
feriority was missed because of the lacking sensitivity of 
the primarily used test to detect viral tropism. A retrospec-
tive analysis, with an exclusion of the additionally found 
X4-tropic virus in patients, by using an advanced version of 
the tropism test demonstrated the expected noninferiority 
of maraviroc. Additionally, patients in the maraviroc arm 
  demonstrated a significantly higher CD4 cell increase com-
pared with the efavirenz arm.
Nonetheless, one of the maraviroc arms was conducted as 
once-daily administration of study drug. This arm was discon-
tinued prematurely due to a lack of efficacy.32 A compilation 
of maraviroc-associated data of the MOTIVATE and MERIT 
trials is shown in Table 1.
Resistance issues of maraviroc
One of the most problematic issues in battling HIV is the 
development of resistances to antiretroviral drugs. Regularly, 
selection of resistant mutants develops under pharmaceutical 
pressure, while viral replication occurs due to the irregular 
intake of medication and/or suboptimal drug levels. In the 
RT, the protease, and the integrase, occurrence of mutations 
may be strongly associated with the drug used: eg, lamivu-
dine regularly causes a M184 V mutation in the RT gene 
locus, which is associated with a resistance to lamivudine 
but reduces viral fitness significantly.33 On the other hand, HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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some protease-associated mutations, such as L90M, may be 
initiated by 1 drug (eg, saquinavir), but may have impact on 
other drugs of the same class (eg, atazanavir and nelfinavir).34 
These mechanisms of direct or cross-resistance are charac-
teristic for drugs interfering with viral enzymes.
In CCR5 inhibitors, there are more escape mechanisms 
for the virus; primarily, the use of the above-mentioned 
coreceptor may change: a R5-using virus might be success-
fully defeated but the virus may switch to use CXCR4 as 
coreceptor. In an in vitro study recently conducted, it has 
been shown that the presence of maraviroc in a cell culture 
does not lead to a switch of R5 viral strains to X4 variants. 
Thus, it appears not to be common for a virus to switch from 
its origin to another tropism, it seems to be rather unusual. 
Therefore, another possibility appears to be more reliable 
with respect to the development of resistance: a preexisting 
X4 virus minority may get selected due to the R5 suppression, 
and as result may lead to resistance against CCR5 inhibitors. 
However, there are also other mechanisms forcing resistance 
to maraviroc: as maraviroc directly interacts with the human 
CCR5, the viral correlate, the env gene with its gp120 and 
gp41, may mutate. Studies showed the changes of the V3 
loop of gp120 lead to resistance, but mutations have also 
been reported in other regions of gp120 and gp41 due to 
the enormous variability of the env gene. Additionally, the 
development of resistance in the presence of CCR5 inhibitors 
does not select always the same mutations.35–39 Consequently, 
the prediction of resistance in CCR5 inhibitors may be more 
complicated and more difficult to interpret than it is with the 
RT or PIs.
A third possibility for the virus to attain infectiveness of 
its combatant maraviroc or other CCR5 inhibitors is the abil-
ity to bind to the coreceptor despite specific drug is bound, 
whether through a competitive replacement due to higher 
affinity than the drug or because of the possibility to bind 
despite a drug-bound receptor.40,41
when to use maraviroc
Taking the above-mentioned facts into account, the conse-
quences of therapeutic use still remain elusive. Nearly, 80% 
of all antiretroviral naive patients harbor R5-tropic virus, and 
therefore, would be eligible for using this drug. However, 
until 2009, the worldwide approvals for maraviroc indicate 
its use only for pretreated patients with R5-tropic HIV-1, 
partly with this requirement alone or partly with the neces-
sity of resistances to other antiretroviral drug. Since 2009, 
maraviroc is licensed in the United States under a statement, 
“for combination antiretroviral treatment of adults infected 
with only CCR5-tropic HIV-1” (US Food and Drug Admin-
istration approval November 20, 2009), which means that it 
can be used also in naive patients. However, this statement 
is directly followed by a special note: “… more subjects 
treated with SELZENTRY® experienced virologic failure and 
developed lamivudine resistance compared to efavirenz …,” 
which puts the indication into perspective. Hence, the use of 
maraviroc in treatment-naive individuals would be accord-
ing to the applicable label, but may induce a higher risk 
for the patients to develop virological failure and acquiring 
resistances. Therefore, maraviroc should be the first choice 
in treatment-naive patients only under special conditions and 
thorough surveillance.
In treatment-experienced subjects, the MOTIVATE stud-
ies demonstrated a benefit of maraviroc compared with the 
placebo arms in virological and immunological responses. 
However, 955 individuals (29.4%) of 3,244 screened patients 
were directly excluded from the studies due to the occur-
rence of X4 or dual/mixed tropism. Overall, in only 61% of 
the initially tested patients, an R5 tropism could be clearly 
Table 1 96-week results of maraviroc studies in patients harboring CCR5-tropic virus
Study MOTIVATE 1 and 2  
pooled data
MERIT primary  
analysis
MERIT post  
hoc analysis
No of patients who used  maraviroc twice a day 426 360 311
Baseline characteristics
  HIV-1 RNA level, mean, copies/mL 4.85 log10 4.86 log10 4.88 log10
  CD4 cell count, median 167 cells/µL 241 cells/µL 236 cells/µL
Virological and immunological responses
    HIV-1 RNA: change from  
baseline, mean, log10 copies/mL
-1.84 Data on file Data on file
  HIV-1 RNA: ,400 copies/mL 50 61.7   64.3
  HIV-1 RNA: ,50 copies/mL 40 57.8   60.5
  CD4 cell count, change from baseline, mean, cells/mm³ 187 224 224
Virological failure after 96 wk% 25 22   22
Abbreviations: CCR5, C-C chemokine receptor type 5; HIV, human immunodeficiency virus.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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demonstrated.29 These results were generated with a later 
revised phenotypic assay (Trofile™, Monogram Bioscience, 
South San Fransico, California, USA). Unfortunately, the 
possible subsequently generated data obtained using the 
enhanced Trofile assay, which is more sensitive, are not 
applicable. Nonetheless, the virological activity of maraviroc 
and the good compatibility could be demonstrated in the 
studies and in clinical practice. However, before starting 
ARV , it needs to be demonstrated that the patient is harboring 
R5-tropic virus, exclusively. Hence, maraviroc serves as an 
enrichment of the armamentarium for HIV treatment.
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